Log in

NYSEAMERICAN:CVMCEL-SCI Stock Price, Forecast & News

$14.30
-0.24 (-1.65 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.13
Now: $14.30
$14.90
50-Day Range N/A
52-Week Range
$5.80
Now: $14.30
$18.00
Volume447,700 shs
Average Volume949,457 shs
Market Capitalization$538.17 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 1.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.06 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:CVM
CUSIPN/A
Phone+1-703-5069460

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$538.17 million
Next Earnings Date8/12/2020 (Estimated)
OptionableOptionable

Receive CVM News and Ratings via Email

Sign-up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter.

CEL-SCI (NYSEAMERICAN:CVM) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of CEL-SCI?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CEL-SCI in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CEL-SCI.

When is CEL-SCI's next earnings date?

CEL-SCI is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for CEL-SCI.

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSEAMERICAN:CVM) announced its quarterly earnings results on Monday, May, 11th. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.01. The business had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.10 million. View CEL-SCI's earnings history.

What price target have analysts set for CVM?

1 equities research analysts have issued twelve-month price objectives for CEL-SCI's shares. Their forecasts range from $23.00 to $23.00. On average, they anticipate CEL-SCI's stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 60.8% from the stock's current price. View analysts' price targets for CEL-SCI.

Has CEL-SCI been receiving favorable news coverage?

Media stories about CVM stock have been trending neutral on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. CEL-SCI earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about CEL-SCI.

Who are some of CEL-SCI's key competitors?

What other stocks do shareholders of CEL-SCI own?

Who are CEL-SCI's key executives?

CEL-SCI's management team includes the following people:
  • Mr. Geert R. Kersten, CEO, Principal Accounting & Financial Officer, Treasurer and Director (Age 60)
  • Ms. Patricia B. Prichep, Sr. VP of Operations & Corp. Sec. (Age 68)
  • Dr. Eyal Talor, Chief Scientific Officer (Age 63)
  • Dr. Daniel H. Zimmerman, Sr. VP of Research & Cellular Immunology (Age 78)
  • Mr. John Cipriano, Sr. VP of Regulatory Affairs (Age 77)

What is CEL-SCI's stock symbol?

CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."

How do I buy shares of CEL-SCI?

Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CEL-SCI's stock price today?

One share of CVM stock can currently be purchased for approximately $14.30.

How big of a company is CEL-SCI?

CEL-SCI has a market capitalization of $538.17 million.

What is CEL-SCI's official website?

The official website for CEL-SCI is www.cel-sci.com.

How can I contact CEL-SCI?

CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at +1-703-5069460.

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.